Clinical Trials Logo

Clinical Trial Summary

Phase Ib: Explore the safety and tolerability of BL-M07D1 to further define RP2D in a variety of solid tumors, including locally advanced or metastatic urinary and gastrointestinal tumors. Phase II: To explore the efficacy of BL-M07D1 in patients with a variety of solid tumors including locally advanced or metastatic HER2-positive/low-expressing urinary and gastrointestinal tumors.


Clinical Trial Description

n/a


Study Design


NCT number NCT06031584
Study type Interventional
Source Sichuan Baili Pharmaceutical Co., Ltd.
Contact Sa Xiao, PHD
Phone +8615013238943
Email xiaosa@baili-pharm.com
Status Recruiting
Phase Phase 1/Phase 2
Start date January 19, 2024
Completion date March 2026